Are there clinical studies supporting NeuroGold's effectiveness for peripheral neuropathy?
Executive summary
Available search results do not identify any clinical trials or peer‑reviewed studies explicitly testing a product or therapy named “NeuroGold” for peripheral neuropathy; the returns instead list academic and institutional peripheral‑neuropathy trials and reviews without mentioning NeuroGold (not found in current reporting) [1] [2] [3] [4] [5] [6]. Major recent reviews and institution trial listings emphasize ongoing studies of drugs, neuromodulation and regenerative approaches, underscoring that high‑quality, sham‑controlled trials remain the standard called for in the field [6] [7].
1. No mention of “NeuroGold” in institutional trial listings
I searched clinical trial pages from multiple University of California centers and related foundations; none of the pages list a trial of a therapy called NeuroGold. UCSD, UCSF, UC Irvine, UC Davis and the UC system trial aggregators show phase II/III drug trials, cryoneurolysis, capsule formulations and platform protocols — but no NeuroGold studies are listed [1] [2] [3] [4] [8]. This absence in major academic clinical‑trial listings indicates available institutional reporting does not document NeuroGold trials (not found in current reporting) [1] [2] [3] [4] [8].
2. The field’s active areas — context for where NeuroGold would fit
Recent trial activity focuses on pharmacotherapies (duloxetine, novel oral agents), procedural interventions (cryoneurolysis) and platform Phase II testing of multiple assets for painful diabetic peripheral neuropathy (PDPN) [1] [2] [4]. Systematic reviews and meta‑analyses in leading journals stress modest overall treatment effects and call for larger, sham‑controlled trials over clinically relevant timeframes — the very standard any claimant like NeuroGold would need to meet to be accepted by the specialty [6] [7].
3. Neuromodulation and “scrambler” evidence — a useful comparison
Noninvasive neuromodulation techniques such as Scrambler Therapy are under evaluation and systematic review; reviews conclude techniques can be safe and potentially beneficial but that data remain insufficient for definitive conclusions [7]. If NeuroGold is a neuromodulatory device or technique, its evidentiary bar is this literature: multiple randomized, sham‑controlled trials and systematic reviews are required before broad clinical endorsement [7] [6].
4. What reputable sources report — clinical trials vs. advocacy and summaries
The Foundation for Peripheral Neuropathy and academic centers list current translational and clinical projects including biomarker work, anti‑AAV assay development and stem‑cell/regenerative research, again without reference to NeuroGold [5]. High‑visibility journals (Lancet Neurology) publish meta‑analyses calling for more rigorous trials — a signal that novel products must produce data that would be captured in these venues or in university trial registries to be credibly supported [5] [6].
5. Possible reasons for the absence of NeuroGold in these sources
Available sources do not state why NeuroGold is absent from academic trial lists or reviews (not found in current reporting). Possible explanations consistent with the pattern here: NeuroGold may be a commercial product without university‑sponsored trials, it may have trials registered outside the captured institutional pages, or it may lack formal clinical evaluation. None of those explanations are claimed in the sources provided, so they remain hypothetical (not found in current reporting) (p1_s1–[5], [1]4).
6. How to verify claims responsibly — practical next steps
To confirm whether NeuroGold has clinical evidence, search clinicaltrials.gov and peer‑reviewed journals for “NeuroGold” or its manufacturer; check regulatory filings (FDA) or university trial registries; and request published outcome data or trial registry IDs from the vendor. The sources here show that credible evidence would likely appear in university trial listings or systematic reviews [1] [2] [6].
Limitations and caveats: the provided search results are broad institutional pages, foundation summaries and a major systematic review; they do not cover every journal or registry. They do not mention NeuroGold specifically (not found in current reporting). If you have a product link, trial identifier, company name or a publication, I can re‑check those exact records and report what the indexed sources show (p1_s1–[1]4).